[The content of fibronectin, fibrinogen, its degradation products and myoglobin in patients with ischemic heart disease].
ELISA using the test systems and a complex of equipment manufactured by Flow Company was employed to study over time the content of fibronectin, fibrinogen, products of its degradation and myoglobin in 178 patients suffering from coronary heart disease (stable and progressive angina pectoris, acute myocardial infarction). The concentration of myoglobin, fibronectin, fibrinogen and products of its degradation was established to depend on the gravity of coronary heart disease and the tame elapsed since the disease onset. In patients with progressive disease, there was an increased consumption of fibronectin which may be due both to its expenditure during blood coagulation and fulfillment of angioprotective function because of exacerbation of systemic atherosclerosis.
Malaia
L T
LT
Volkov
V I
VI
Topchiĭ
I I
II
Dykun
Ia V
IaV
Shuliak
L N
LN
D000328:Adult; D000787:Angina Pectoris / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005340:Fibrinogen / Q000032:analysis*; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D009211:Myoglobin / Q000097:blood*; D005082:Physical Exertion; D015912:Thrombolytic Therapy; D013997:Time Factors
D005338:Fibrin Fibrinogen Degradation Products; D005353:Fibronectins; D009211:Myoglobin; D005340:Fibrinogen
Soderzhanie fibronektina, fibrinogena, produktov ego degradatsii i mioglobina u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.